Fulcrum Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for serious genetic diseases and other rare conditions.
No entity score yet. This entity needs at least one linked article with an entity impact vote and focus support.
Showing 1-1 of 1 linked article
Page 1 of 1
Fulcrum Therapeutics saw its stock drop sharply after the company said it was ending development of its sickle cell disease drug pociredir, and Kaplan Fox & Kilsheimer LLP said it is investigating possible securities law violations.
Per-entity impact from this article: None